Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male or female adults,~* 18 to 50 years of age (21 to 50 years of age for volunteers in Rwanda),~* who do not report high-risk behaviour for HIV infection,~* who are available for the duration of the trial,~* who are willing to undergo HIV testing,~* use an effective method of contraception, and~* who, in the opinion of the principal investigator or designee, understand the study and who provide written informed consent.~Exclusion Criteria:~* confirmed HIV infection,~* pregnancy and lactation,~* significant acute or chronic disease,~* clinically significant laboratory abnormalities,~* recent vaccination or receipt of a blood product,~* previous receipt of an HIV vaccine, and~* previous severe local or systemic reactions to vaccination or history of severe allergic reactions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group A: SeV-G(NP) followed by Ad35-GRIN (Type: EXPERIMENTAL): SeV-G(NP) (IN) at 2x10\^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10\^10 vp at Month 4. (Vaccine/Placebo = 12/4)
- Group B: SeV-G(NP) followed by Ad35-GRIN (Type: EXPERIMENTAL): SeV-G(NP) (IN) at 2x10\^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10\^10 vp at Month 4. (Vaccine/Placebo = 12/4)
- Group C: Ad35-GRIN followed by SeV-G(NP) (Type: EXPERIMENTAL): Ad35-GRIN (IM) at 1x10\^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10\^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
- Group D: SeV-G(NP) only (Type: EXPERIMENTAL): SeV-G(NP) (IN) at 2x10\^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)

Based on this trial design, predict the completion outcome and termination type (if applicable).